Indivior PLC Announces Promising Study on SUBLOCADE® for Opioid Use Disorder During Pregnancy

London, May 1, 2025 — Indivior PLC, a global biopharmaceutical company based in Slough, United Kingdom, has announced the publication of a study highlighting the potential of SUBLOCADE® (buprenorphine depot injection) as a treatment option for opioid use disorder (OUD) during and after pregnancy. The study, published in the American Journal on Addictions, presents promising preliminary safety data for pregnant women with OUD.

Study Findings

The study evaluated the use of monthly SUBLOCADE during pregnancy and found no increased risk of birth defects, miscarriage, or maternal complications compared to general population rates. The research involved a retrospective analysis of three data sources, including clinical case studies and postmarketing surveillance. Notably, all four clinical case study patients delivered healthy full-term infants, with no reported birth defects in the majority of known cases.

Addressing a Critical Knowledge Gap

This study addresses a critical knowledge gap in treating pregnant patients with OUD. Historically, limited data has been available, with only 21% of pregnancies reporting outcomes in postmarketing surveillance. The small patient cohort of four cases in the clinical studies highlights the need for further research, despite the promising preliminary results.

Potential Bias and Future Research

It is important to note that the study was funded by Indivior, which could introduce bias. However, the findings suggest that SUBLOCADE may offer a safe treatment option for pregnant women with OUD, potentially improving outcomes for both mothers and infants.

Company Overview

Indivior PLC is listed on the London Stock Exchange and specializes in discovering, developing, and commercializing medications for substance use disorders and serious mental illnesses. As of April 28, 2025, the company’s close price was 858.5 GBP, with a market capitalization of 1.24 billion GBP. The company’s price-to-earnings ratio stands at 680.38.

Market Context

The announcement comes as the FTSE 100 continues its longest winning streak in over eight years, although gains have been limited due to economic data from China and anticipation of upcoming economic indicators and corporate earnings from the US. Indivior’s stock performance is part of a broader market trend, with stocks holding higher at the end of the month ahead of significant economic data releases.

For more information, visit Indivior’s website .